Bosentan Hydrate

endothelin receptor antagonist CAS# 157212-55-0

Bosentan Hydrate

Catalog No. BCC4494----Order now to get a substantial discount!

Product Name & Size Price Stock
Bosentan Hydrate: 5mg $12 In Stock
Bosentan Hydrate: 10mg Please Inquire In Stock
Bosentan Hydrate: 20mg Please Inquire Please Inquire
Bosentan Hydrate: 50mg Please Inquire Please Inquire
Bosentan Hydrate: 100mg Please Inquire Please Inquire
Bosentan Hydrate: 200mg Please Inquire Please Inquire
Bosentan Hydrate: 500mg Please Inquire Please Inquire
Bosentan Hydrate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Bosentan Hydrate

Number of papers citing our products

Chemical structure

Bosentan Hydrate

3D structure

Chemical Properties of Bosentan Hydrate

Cas No. 157212-55-0 SDF Download SDF
PubChem ID 185462 Appearance Powder
Formula C27H31N5O7S M.Wt 569.63
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (175.55 mM)
Ethanol : 50 mg/mL (87.78 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide;hydrate
SMILES CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC.O
Standard InChIKey SXTRWVVIEPWAKM-UHFFFAOYSA-N
Standard InChI InChI=1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Bosentan Hydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Bosentan Hydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Bosentan Hydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7555 mL 8.7776 mL 17.5553 mL 35.1105 mL 43.8881 mL
5 mM 0.3511 mL 1.7555 mL 3.5111 mL 7.0221 mL 8.7776 mL
10 mM 0.1756 mL 0.8778 mL 1.7555 mL 3.5111 mL 4.3888 mL
50 mM 0.0351 mL 0.1756 mL 0.3511 mL 0.7022 mL 0.8778 mL
100 mM 0.0176 mL 0.0878 mL 0.1756 mL 0.3511 mL 0.4389 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Bosentan Hydrate

IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 μM in P388/dx cells.

A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. By competitively binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle, Bosentan offset the effect of endothelin which is an extremely potent endogenous vasoconstrictor and broncho-constrictor. In addition, Bosentan decreases both pulmonary and systemic vascular resistance and is particularly applied in the treatment of pulmonary arterial hypertension. [1]

In vitro: A study was performed in vitro to measure the influence of Bosentan on the angiogenic performance of dermal microvascular endothelial cells (MVECs) and to detect the capacity of Bosentan in offsetting the antiangiogenic effects of systemic sclerosis sera. It was found that Bosentan significantly increased cell viability and offset the antiangiogenic effects of systemic sclerosis sera on dermal MVECs. [2]

In vivo: A study was conducted to investigate the effect of Bosentan on plasma leptin level after myocardial infarction in Wistar rats. After oral administration of Bosentan once daily at the dose of 100 mg/kg for 2 days, concentration of leptin in plasma significantly increased. This finding revealed that Bosentan played an crucial role on regulating leptin concentration in ischemic cardiovascular pathology. [1]

Clinical trials: A double-blind, placebo-controlled clinical trial was conducted to study the effect of bosentan on exercise capacity in a larger number of patients. 213 patients with pulmonary arterial hypertension were administered with 62.5 mg Bosentan twice daily for 4 weeks followed by either of two doses of Bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. It was found that 125 mg Bosentan was well tolerated and beneficial in patients with pulmonary arterial hypertension. [3]

References:
[1] Ostrowski RP, Januszewski SA, Kowalska ZA and Kapuscinski A.  Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats. Pathophysiology. 2003 Sep; 9(4): 249-56.
[2]Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, Guiducci S.  Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clin Exp Rheumatol. 2015 Aug; 33(4 Suppl 91): S148-52.
[3]Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM et, al.  Bosentan therapy for pulmonary arterial hypertension. New Engl J Med. 2002 Mar; 346 (12): 896-903.

Featured Products
New Products
 

References on Bosentan Hydrate

Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.[Pubmed:28008226]

Drug Des Devel Ther. 2016 Dec 13;10:4017-4030.

The objectives of this study were to prepare Bosentan Hydrate (BST) microparticles as dry powder inhalations (DPIs) via spray drying and jet milling under various parameters, to comprehensively characterize the physicochemical properties of the BST hydrate microparticles, and to evaluate the aerosol dispersion performance and dissolution behavior as DPIs. The BST microparticles were successfully prepared for DPIs by spray drying from feeding solution concentrations of 1%, 3%, and 5% (w/v) and by jet milling at grinding pressures of 2, 3, and 4 MPa. The physicochemical properties of the spray-dried (SD) and jet-milled (JM) microparticles were determined via scanning electron microscopy, atomic force microscopy, dynamic light scattering particle size analysis, Karl Fischer titration, surface analysis, pycnometry, differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared spectroscopy. The in vitro aerosol dispersion performance and drug dissolution behavior were evaluated using an Anderson cascade impactor and a Franz diffusion cell, respectively. The JM microparticles exhibited an irregular corrugated surface and a crystalline solid state, while the SD microparticles were spherical with a smooth surface and an amorphous solid state. Thus, the in vitro aerosol dispersion performance and dissolution behavior as DPIs were considerably different due to the differences in the physicochemical properties of the SD and JM microparticles. In particular, the highest grinding pressures under jet milling exhibited excellent aerosol dispersion performance with statistically higher values of 56.8%+/-2.0% of respirable fraction and 33.8%+/-2.3% of fine particle fraction and lower mass median aerodynamic diameter of 5.0+/-0.3 mum than the others (P<0.05, analysis of variance/Tukey). The drug dissolution mechanism was also affected by the physicochemical properties that determine the dissolution kinetics of the SD and JM microparticles, which were well fitted into the Higuchi and zero-order models, respectively.

Description

Bosentan hydrate is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively.

Keywords:

Bosentan Hydrate,157212-55-0,Natural Products,Endothelin Receptor, buy Bosentan Hydrate , Bosentan Hydrate supplier , purchase Bosentan Hydrate , Bosentan Hydrate cost , Bosentan Hydrate manufacturer , order Bosentan Hydrate , high purity Bosentan Hydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: